Supplementary Table S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial

Supplementary Table S2 | Criteria for defining DLT. AE, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicities; GI, gastrointestinal; LLN, lower limit of normal; SOC, standard of care; ULN, upper limit of normal.